Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-63178
Dummer, R; Beyer, M; Hymes, K; Epping, M T; Bernards, R; Steinhoff, M; Sterry, W; Kerl, H; Heath, K; Ahern, J D; Hardwick, J S; Garcia-Vargas, J; Baumann, K; Rizvi, S; Frankel, S R; Whittacker, S J; Assaf, C (2012). Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. Leukemia and Lymphoma, 53(8):1501-1508.
PDF - Registered users only
The retinoid X receptor (RXR)-agonist bexarotene and the histone deacetylase inhibitor (HDACI) vorinostat are each established monotherapies for cutaneous T-cell lymphomas (CTCLs). We investigated the combination of HDACI and retinoic acid receptor (RAR)/RXR agonists in vitro and in a phase I, multicenter, open-label, two-part dose-escalation study. The combination of bexarotene with a HDACI in vitro leads to cooperative activation of gene transcription and reduction of cell viability in human tumor cell lines. The primary clinical objective was to determine the maximum tolerated dose (MTD) of bexarotene plus vorinostat in 23 patients with CTCLs. The MTD for part I was established at vorinostat 200 mg/day plus bexarotene 300 mg/m 2 /day. The
MTD for part II was not reached. Four patients had an active response and seven patients experienced pruritus relief. We conclude that concomitant administration of vorinostat and bexarotene is feasible only if lower doses of each drug are administered relative to the product label monotherapy doses.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic|
|DDC:||610 Medicine & health|
|Date:||8 January 2012|
|Deposited On:||09 Jul 2012 09:00|
|Last Modified:||06 Jan 2014 18:15|
|Citations:||Web of Science®. Times Cited: 7|
Scopus®. Citation Count: 9
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page